A case of severe acute necrotizing pancreatitis after administration of sitagliptin

Clinical Medicine Insights: Case Reports

Volumn 6, Issue , 2013, Pages 23-27

  Sue, Mariko ^a   Yoshihara, Aya ^a   Kuboki, Koji ^a   Hiroi, Naoki ^a   Yoshino, Gen ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetes mellitus; DPP 4 inhibitor; Pancreatitis; Sitagliptin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA AMYLASE PANCREAS ISOENZYME; AMYLASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; INSULIN; METFORMIN; PANCREAS ENZYME; SITAGLIPTIN; VOGLIBOSE;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ACUTE HEMORRHAGIC PANCREATITIS; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIABETES CONTROL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; HYPERLIPIDEMIA; JAPANESE; LEUKOCYTE COUNT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; RESPIRATORY FAILURE;

EID: 84874220518     PISSN: 11795476     EISSN: None     Source Type: Journal    
DOI: 10.4137/CCRep.S10856     Document Type: Article

References (26)

1. Scheen AJ. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favorable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med. 2012;23(2):126-31.
2. Mayumi T, Ura H, Arata S, et al. Working Group for the Practical Guidelines for Acute Pancreatitis. Japanese Society of Emergency Abdominal Medicine. J Hepatobiliary Pancreat Surg. 2002;9(4):413-22.
3. Sekimoto M, Takada T, Kawarada Y, et al. Japanese guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobiliary Pancreat Surg. 2006;13(1):10-24.
4. McArthur KE. Review article: drug-induced pancreatitis. Aliment Pharmacol Ther. 1996;10(1):23-38.
5. Takada T, Kawarada Y, Hirata K, et al. Japanese guidelines for the management of acute pancreatitis: cutting-edge information. J Hepatobiliary Pancreat Surg. 2006;13(1):2-6.
6. Deshpande PR, Khera K, Thunga G, Hande M, Gouda ST, Nagappa AN. Atorvastatin-induced acute pancreatitis. J Pharmacol Pharmacother. 2011; 2(1):40-2.
7. Prajapati S, Shan S, Desai C, Desai M, Dikshit RK. Atorvastatin-induced pancreatitis. Indian J Pharmacol. 2010;42(5):324-5.
8. Kanbay M, Sekuk H, Yilmaz U, Gur G, Boyacioglu S. Acute pancreatitis associated with combined lisinopril and atorvastatin therapy. Dig Dis. 2005;23(1):92-4.
9. Singh S, Nautiyal A, Dolan JG. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect? JOP. 2004;5(6):502-4.
10. Miltiadous G, Anthopoulou A, Elisaf M. Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. JOP. 2003;4(1): 20-1.
11. Belaiche G, Ley G, Slama JL. Acute pancreatitis associated with atorvastatin therapy. Gastroenterol Clin Biol. 2000;24(4):471-2.
12. Molina Infante J, Prieto Bermejo AB, Perez Gallardo B, Fernandez Bermejo M. Toxic metformin-associated acute pancreatitis without kidney failure. Med Clin (Barc). 2008;131(13):519.
13. Audia P, Feinfeld DA, Dubrow A, Winchester JF. Metformin-induced lactic acidosis and acute pancreatitis precipitated by diuretic, celecoxib, and candesartan-associated acute kidney dysfunction. Clin Toxicol (Phila). 2008; 46(2):164-6.
14. Fimognari FL, Corsonello A, Pastorell R, Antonelli-Incalzi R. Metformin-induced pancreatitis: a possible adverse drug effect during acute renal failure. Diabetes Care. 2006;29(5):1183.
15. Mallick S. Metformin induced acute pancreatitis precipitated by renal failure. Postgrad Med J. 2004;80(942):239-40.
16. Ben MH, Thabet H, Zaghdoudi I, Amamou M. Metformin associated acute pancreatitis. Ven Hum Toxicol. 2002;44(1):47-8.
17. Garg R, Hussey C, Ibrahim S. Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report. Diabet Med. 2010;27(4):485-6.
18. Iyer SN, Drake AJ 3rd, West RL, Mendez CE, Tanenberg RJ. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr Pract. 2012;18(1):e10-3.
19. Matsushita M, Yamada Y, Katou Y, Nakano M, Yamada S. Oral presentation in 582nd Japanese society of internal medicine, Kanto region. Unpublished observation.
20. Girgis CM, Champion BL. Vildagliptin-induced acute pancreatitis. Endocr pract. 2011;17(3):e48-50.
21. Raschi E, Piccinni C, Poluzzi E, Marchesini F, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol. Oct 19, 2011. [Epub ahead of print.]
22. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes. 2009;58(7):1604-15.
23. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-6.
24. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes. 2009;58(9):2148-61.
25. Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010;53(1):153-9.
26. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019-27.